RU2332229C2 - Способ введения молекул glp-1 - Google Patents

Способ введения молекул glp-1 Download PDF

Info

Publication number
RU2332229C2
RU2332229C2 RU2004127916/15A RU2004127916A RU2332229C2 RU 2332229 C2 RU2332229 C2 RU 2332229C2 RU 2004127916/15 A RU2004127916/15 A RU 2004127916/15A RU 2004127916 A RU2004127916 A RU 2004127916A RU 2332229 C2 RU2332229 C2 RU 2332229C2
Authority
RU
Russia
Prior art keywords
glp
xaa
glu
seq
gly
Prior art date
Application number
RU2004127916/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2004127916A (ru
Inventor
Мохаммед Эмин ХАН (US)
Мохаммед Эмин ХАН
Брайан Эдвард ДЖОУНС (US)
Брайан Эдвард ДЖОУНС
Джон МакНейл МАКДЖИЛЛ (US)
Джон МакНейл МАКДЖИЛЛ
Original Assignee
Эмисфире Текнолоджис Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эмисфире Текнолоджис Инк. filed Critical Эмисфире Текнолоджис Инк.
Publication of RU2004127916A publication Critical patent/RU2004127916A/ru
Application granted granted Critical
Publication of RU2332229C2 publication Critical patent/RU2332229C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
    • A01N37/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing the group —CO—N<, e.g. carboxylic acid amides or imides; Thio analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pest Control & Pesticides (AREA)
  • Child & Adolescent Psychology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Agronomy & Crop Science (AREA)
  • Emergency Medicine (AREA)
  • Plant Pathology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Environmental Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
RU2004127916/15A 2002-02-20 2003-02-07 Способ введения молекул glp-1 RU2332229C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35818402P 2002-02-20 2002-02-20
US60/358,184 2002-02-20

Publications (2)

Publication Number Publication Date
RU2004127916A RU2004127916A (ru) 2005-04-10
RU2332229C2 true RU2332229C2 (ru) 2008-08-27

Family

ID=27765952

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004127916/15A RU2332229C2 (ru) 2002-02-20 2003-02-07 Способ введения молекул glp-1

Country Status (16)

Country Link
US (5) US20050148497A1 (enExample)
EP (2) EP1478233B1 (enExample)
JP (2) JP4417113B2 (enExample)
KR (2) KR101165431B1 (enExample)
CN (1) CN1332711C (enExample)
AU (1) AU2003208945B2 (enExample)
BR (1) BR0307727A (enExample)
CA (1) CA2473340C (enExample)
ES (1) ES2614603T3 (enExample)
IL (2) IL163278A (enExample)
MX (1) MXPA04008068A (enExample)
NZ (1) NZ534125A (enExample)
PL (1) PL209734B1 (enExample)
RU (1) RU2332229C2 (enExample)
WO (1) WO2003072195A2 (enExample)
ZA (1) ZA200406626B (enExample)

Families Citing this family (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7084279B1 (en) * 1999-02-11 2006-08-01 Emisphere Technologies Inc. Oxadiazole compounds and compositions for delivering active agents
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
MXPA04008068A (es) * 2002-02-20 2004-11-26 Lilly Co Eli Metodo para administrar moleculas de glp-1.
US7635463B2 (en) * 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
ATE494010T1 (de) * 2002-02-27 2011-01-15 Pharmain Corp Zusammensetzungen zur abgabe von therapeutika und anderen materialien und verfahren zu ihrer herstellung und verwendung
US20050260259A1 (en) * 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
ES2425392T3 (es) 2002-03-20 2013-10-15 Mannkind Corporation Cartucho para un aparato de inhalación
EP1658273B1 (en) 2003-08-20 2007-01-03 Eli Lilly And Company Compounds, methods and formulations for the oral delivery of a glucagon like peptide (glp)-1 compound or an melanocortin 4 receptor (mc4) agonist peptide
ES2286679T3 (es) 2003-08-20 2007-12-01 Eli Lilly And Company Compuestos, procedimientos y formulaciones para la liberacion oral de un compuesto de peptido de tipo glucagon (glp)-1 o un peptido agonist a del receptor de melanocortina 4 (mc4).
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
DK1786784T3 (da) 2004-08-20 2011-02-14 Mannkind Corp Katalyse af diketopiperazinsyntese
BR122019022692B1 (pt) 2004-08-23 2023-01-10 Mannkind Corporation Composição terapêutica em pó seco contendo dicetopiperazina, pelo menos um tipo de cátion e um agente biologicamente ativo
EP1784115B1 (en) * 2004-08-23 2013-05-01 Reckitt Benckiser N.V. Detergent dispensing device
US7442682B2 (en) 2004-10-19 2008-10-28 Nitto Denko Corporation Transepithelial delivery of peptides with incretin hormone activities
GB0427603D0 (en) * 2004-12-16 2005-01-19 Novartis Ag Organic compounds
US8975227B2 (en) * 2005-07-15 2015-03-10 Emisphere Technologies, Inc. Intraoral dosage forms of glucagon
WO2007033372A2 (en) 2005-09-14 2007-03-22 Mannkind Corporation Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
CA2628400A1 (en) * 2005-11-07 2007-05-10 Reckitt Benckiser N.V. Dosage element
WO2007076371A2 (en) 2005-12-19 2007-07-05 Pharmain Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
US20100065084A1 (en) * 2006-01-21 2010-03-18 Reckitt Benckiser N.V. Multi-Dosing Detergent Delivery Device
DK1986679T3 (da) 2006-02-22 2017-11-20 Mannkind Corp Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof
BRPI0709964A2 (pt) * 2006-04-14 2011-08-02 Mannkind Corp formulações farmacêuticas contendo peptìdeo glucagon do tipo 1 (glp-1)
WO2008014232A2 (en) * 2006-07-24 2008-01-31 Emisphere Technologies, Inc. Pharmaceutical formulations for the treatment of alzheimer's disease
JP5577094B2 (ja) * 2006-08-31 2014-08-20 エミスフェアー・テクノロジーズ・インク 活性薬剤を送達するための化合物及び組成物
WO2008053175A1 (en) * 2006-10-30 2008-05-08 Reckitt Benckiser N.V. Multi-dosing detergent delivery device
GB0621574D0 (en) * 2006-10-30 2006-12-06 Reckitt Benckiser Nv Multi-dosing detergent delivery device
GB0621576D0 (en) 2006-10-30 2006-12-06 Reckitt Benckiser Nv Device status indicator
GB0621570D0 (en) * 2006-10-30 2006-12-06 Reckitt Benckiser Nv Multi-dosing detergent delivery device
EP2089502A1 (en) * 2006-10-30 2009-08-19 Reckitt Benckiser Production (Poland) Sp. Zo. O. Compressed detergent composition
GB0621569D0 (en) * 2006-10-30 2006-12-06 Reckitt Benckiser Nv Mounting device
GB0621572D0 (en) * 2006-10-30 2006-12-06 Reckitt Benckiser Nv Multi-dosing detergent delivery device
GB0621578D0 (en) * 2006-10-30 2006-12-13 Reckitt Benckiser Nv Multi-dosing detergent delivery device
GB0710229D0 (en) * 2007-05-30 2007-07-11 Reckitt Benckiser Nv Detergent dosing device
GB0710231D0 (en) * 2007-05-30 2007-07-11 Reckitt Benckiser Nv Refill device for multi-dosing detergent delivery device
JP2009019027A (ja) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
US7960336B2 (en) * 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) * 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
CA3153292A1 (en) 2008-06-13 2009-12-17 Mannkind Corporation A dry powder inhaler and system for drug delivery
CN102065942B (zh) 2008-06-20 2013-12-11 曼金德公司 用于对吸入工作进行实时描绘的交互式设备和方法
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
ES2614427T3 (es) 2008-11-07 2017-05-31 The General Hospital Corporation Fragmentos C-terminales de péptido glucagonoide 1 (GLP-1)
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
PL2405963T3 (pl) 2009-03-11 2014-04-30 Mannkind Corp Urządzenie, układ i sposób pomiaru oporu inhalatora
KR20180036807A (ko) 2009-06-12 2018-04-09 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
WO2011080103A1 (en) 2009-12-16 2011-07-07 Novo Nordisk A/S Double-acylated glp-1 derivatives
US20130150323A1 (en) * 2010-02-04 2013-06-13 Urigen Pharmaceuticals, Inc Use of oral heparin preparations to treat urinary tract diseases and conditions
RU2571331C1 (ru) 2010-06-21 2015-12-20 Маннкайнд Корпорейшн Системы и способы доставки сухих порошковых лекарств
WO2012061466A2 (en) 2010-11-02 2012-05-10 The General Hospital Corporation Methods for treating steatotic disease
RS60321B1 (sr) 2010-12-16 2020-07-31 Novo Nordisk As Čvrste kompozicije koje sadrže glp-1 agonist i so n-(8-(2- hidroksibenzoil)amino)kaprilne kiseline
KR101940832B1 (ko) 2011-04-01 2019-01-21 맨카인드 코포레이션 의약 카트리지용 블리스터 패키지
DK2696687T3 (en) 2011-04-12 2017-02-06 Novo Nordisk As Double-acylated GLP-1 derivatives
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
WO2013006692A2 (en) 2011-07-06 2013-01-10 The General Hospital Corporation Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)
EP2776053A1 (en) 2011-10-24 2014-09-17 MannKind Corporation Methods and compositions for treating pain
HUE042757T2 (hu) 2012-03-22 2019-07-29 Novo Nordisk As Szállító szert tartalmazó készítmények és elõállításuk
RS58636B1 (sr) 2012-03-22 2019-05-31 Novo Nordisk As Kompozicije koje sadrže sredstvo za isporuku i njihova priprema
PL2827885T3 (pl) 2012-03-22 2019-01-31 Novo Nordisk A/S Kompozycje peptydów GLP-1 i ich otrzymywanie
WO2013189988A1 (en) 2012-06-20 2013-12-27 Novo Nordisk A/S Tablet formulation comprising a peptide and a delivery agent
CN104619369B (zh) 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
EP2911690A1 (en) 2012-10-26 2015-09-02 MannKind Corporation Inhalable influenza vaccine compositions and methods
HRP20181300T1 (hr) 2012-12-21 2018-10-05 Sanofi Derivati eksendina-4 kao dvostruki glp1/gip- ili trostruki glp1/gip/glukagon agonisti
AU2014228415B2 (en) 2013-03-15 2018-08-09 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
KR20210086717A (ko) 2013-05-02 2021-07-08 노보 노르디스크 에이/에스 Glp-1 화합물의 경구 투여
CA2918369C (en) 2013-07-18 2021-06-29 Mannkind Corporation Heat-stable dry powder pharmaceutical compositions and methods
WO2015021064A1 (en) 2013-08-05 2015-02-12 Mannkind Corporation Insufflation apparatus and methods
EP3033112B1 (en) 2013-08-15 2020-10-07 Novo Nordisk A/S Glp-1 derivatives, and uses thereof
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
EP3080149A1 (en) 2013-12-13 2016-10-19 Sanofi Dual glp-1/glucagon receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
MY197023A (en) 2015-12-23 2023-05-22 Amgen Inc Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
EA201992502A1 (ru) 2017-06-20 2020-04-22 Эмджен Инк. Способ лечения или уменьшения интенсивности метаболических нарушений с применением белков, связывающих рецептор гастроингибиторного пептида (gipr), в комбинации с агонистами glp-1
WO2018237095A1 (en) 2017-06-21 2018-12-27 Amgen Inc. METHOD OF TREATING OR ENHANCING METABOLIC DISORDERS USING ANTAGONISTIC BINDING PROTEINS FOR AGONIST FUSION PROTEINS FROM THE GASTRIC INHIBITOR PEPTIDE RECEPTOR (GIPR) / GLP-1 RECEPTOR
MX2020001525A (es) 2017-08-24 2020-03-20 Novo Nordisk As Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
CN111683676B (zh) 2018-02-02 2024-06-18 诺和诺德股份有限公司 包含glp-1激动剂、n-(8-(2-羟基苯甲酰基)氨基)辛酸的盐和润滑剂的固体组合物
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
IL294520A (en) 2020-02-18 2022-09-01 Novo Nordisk As Pharmaceutical formulations

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6329336B1 (en) * 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides
RU2195443C2 (ru) * 1996-07-31 2002-12-27 Байер Корпорейшн Замещенные биарильные соединения или замещенные пиридины и фармацевтические композиции на их основе
RU2247575C2 (ru) * 1999-01-14 2005-03-10 Амилин Фармасьютикалз, Инк. Способы подавления глюкагона

Family Cites Families (100)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US554155A (en) * 1896-02-04 Hose-band
US5614492A (en) * 1986-05-05 1997-03-25 The General Hospital Corporation Insulinotropic hormone GLP-1 (7-36) and uses thereof
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
CA1320905C (en) * 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
DE3729209A1 (de) 1987-09-01 1989-03-09 Boehringer Mannheim Gmbh Verwendung von bezafibrat zur behandlung von diabetes
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
JP2911496B2 (ja) * 1989-09-11 1999-06-23 帝國製薬株式会社 生理活性ポリペプチド含有高吸収性経膣剤
CA2073856C (en) 1990-01-24 2002-12-03 Douglas I. Buckley Glp-1 analogs useful for diabetes treatment
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5122539A (en) * 1990-02-12 1992-06-16 Center For Innovative Technology Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
US6077509A (en) * 1990-03-30 2000-06-20 Autoimmune, Inc. Peptide fragments of myelin basic protein
US5780599A (en) * 1990-07-13 1998-07-14 Novo Nordisk A/S Growth hormone crystals and a process for production of growth hormone crystals
US5629020A (en) * 1994-04-22 1997-05-13 Emisphere Technologies, Inc. Modified amino acids for drug delivery
US5714167A (en) * 1992-06-15 1998-02-03 Emisphere Technologies, Inc. Active agent transport systems
US5541155A (en) * 1994-04-22 1996-07-30 Emisphere Technologies, Inc. Acids and acid salts and their use in delivery systems
US6099856A (en) * 1992-06-15 2000-08-08 Emisphere Technologies, Inc. Active agent transport systems
US5693338A (en) * 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US5447728A (en) * 1992-06-15 1995-09-05 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5451410A (en) * 1993-04-22 1995-09-19 Emisphere Technologies, Inc. Modified amino acids for encapsulating active agents
US5443841A (en) * 1992-06-15 1995-08-22 Emisphere Technologies, Inc. Proteinoid microspheres and methods for preparation and use thereof
US6221367B1 (en) 1992-06-15 2001-04-24 Emisphere Technologies, Inc. Active agent transport systems
US5578323A (en) * 1992-06-15 1996-11-26 Emisphere Technologies, Inc. Proteinoid carriers and methods for preparation and use thereof
US5837822A (en) * 1992-01-27 1998-11-17 Icos Corporation Humanized antibodies specific for ICAM related protein
DK36392D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US5811127A (en) * 1992-06-15 1998-09-22 Emisphere Technologies, Inc. Desferrioxamine oral delivery system
US5792451A (en) * 1994-03-02 1998-08-11 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
KR0154880B1 (ko) 1992-06-15 1998-10-15 피터 알.셰어러 글루카곤-유사 펩티드 및 인슐리노트로핀 유도체
SE9302278D0 (sv) * 1992-10-28 1993-07-02 Kabi Pharmacia Ab Growth hormone
US5888511A (en) * 1993-02-26 1999-03-30 Advanced Biotherapy Concepts, Inc. Treatment of autoimmune diseases, including AIDS
NZ250844A (en) 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
US6610329B2 (en) * 1993-04-22 2003-08-26 Emisphere Technologies Inc. Compositions for the delivery of antigens
US5643957A (en) 1993-04-22 1997-07-01 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5766633A (en) * 1993-04-22 1998-06-16 Emisphere Technologies, Inc. Oral drug delivery compositions and methods
US5958457A (en) * 1993-04-22 1999-09-28 Emisphere Technologies, Inc. Compositions for the delivery of antigens
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
WO1995003827A1 (en) * 1993-07-30 1995-02-09 Kennedy Institute Of Rheumatology Method for treating multiple sclerosis
AU7531094A (en) 1993-08-24 1995-03-21 Novo Nordisk A/S Protracted glp-1
US5837702A (en) * 1993-10-07 1998-11-17 Bristol-Myers Squibb Co. 4-arylamino-benzopyran and related compounds
US5705483A (en) * 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
CA2137206A1 (en) 1993-12-09 1995-06-10 John A. Galloway Glucagon-like insulinotropic peptides, compositions and methods
US5574018A (en) * 1994-07-29 1996-11-12 Amgen Inc. Conjugates of vitamin B12 and proteins
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
AU4298596A (en) 1994-12-23 1996-07-19 Novo Nordisk A/S Protracted glp-1 compositions
US5565558A (en) * 1994-12-30 1996-10-15 Mccully; Kilmer S. Thioretinaco ozonide and enhanced biological activity of thioretinaco ozonide in combination with interferon
AU5360796A (en) * 1995-03-09 1996-10-02 Neurocrine Biosciences, Inc. Peptide analogues of human myelin basic protein useful in treating multiple sclerosis
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
BR9604880A (pt) 1995-03-31 1998-05-19 Emisphere Tech Inc Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US5989539A (en) 1995-03-31 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO1997036480A1 (en) 1996-03-29 1997-10-09 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5965121A (en) 1995-03-31 1999-10-12 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US6001347A (en) * 1995-03-31 1999-12-14 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
US5820881A (en) * 1995-04-28 1998-10-13 Emisphere Technologies, Inc. Microspheres of diamide-dicarboxylic acids
US5766620A (en) * 1995-10-23 1998-06-16 Theratech, Inc. Buccal delivery of glucagon-like insulinotropic peptides
US5849322A (en) * 1995-10-23 1998-12-15 Theratech, Inc. Compositions and methods for buccal delivery of pharmaceutical agents
US6184223B1 (en) * 1995-10-27 2001-02-06 Molecumetics Ltd. Reverse-turn mimetics and methods relating thereto
US5716946A (en) * 1996-02-13 1998-02-10 Wisconsin Alumni Research Foundation Multiple sclerosis treatment
ES2319936T5 (es) 1996-08-08 2013-06-24 Amylin Pharmaceuticals, Inc. Regulación de la motilidad gastrointestinal
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
CZ300837B6 (cs) 1996-08-30 2009-08-26 Novo Nordisk A/S Deriváty GLP-1(7-37) nebo jeho analogy, farmaceutický prostredek je obsahující a jejich použití
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
DE69732572T2 (de) 1996-11-12 2005-12-29 Novo Nordisk A/S Verwendung von glp-1 peptiden
US6313088B1 (en) * 1997-02-07 2001-11-06 Emisphere Technologies, Inc. 8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US5773647A (en) * 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
ATE324907T1 (de) * 1997-02-07 2006-06-15 Emisphere Tech Inc Verbindung und arzneizusammensetzung zur verabreichung von wirkstoffen
US5990166A (en) * 1997-02-07 1999-11-23 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
JP2002510193A (ja) 1997-03-31 2002-04-02 イーライ・リリー・アンド・カンパニー グルカゴン様ペプチド−１類似体
AU749914B2 (en) 1997-08-08 2002-07-04 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
NZ504258A (en) 1997-11-14 2002-12-20 Amylin Pharmaceuticals Inc Exendin 3 and 4 agonist compounds for the treatment of diabetes
EP1032587B2 (en) 1997-11-14 2013-03-13 Amylin Pharmaceuticals, Inc. Novel exendin agonist compounds
US6380357B2 (en) * 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
US6334213B1 (en) * 1998-01-20 2001-12-25 Preview Systems Merging of separate executable computer programs to form a single executable computer program
DE69936446T2 (de) 1998-02-13 2008-03-06 Amylin Pharmaceuticals, Inc., San Diego Inotropische und diuretische effekte von exendin und glp-1
WO1999043708A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
DE69942306D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As Abkömmlinge von glp-1 analogen
US6009856A (en) * 1998-05-27 2000-01-04 Caterpillar Inc. Fuel injector isolation
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
US6121249A (en) * 1998-07-01 2000-09-19 Donald L. Weissman Treatment and prevention of cardiovascular diseases with help of aspirin, antioxidants, niacin, and certain B vitamins
JP2002523333A (ja) 1998-07-31 2002-07-30 ノボ ノルディスク アクティーゼルスカブ Ｉｉ型糖尿病を予防するためのｇｌｐ−１及び類似体の利用
MY155270A (en) 1998-09-24 2015-09-30 Lilly Co Eli Use of glp-1 or analogs in treatment of stroke
CN1338924A (zh) 1999-01-08 2002-03-06 艾米斯菲尔技术有限公司 聚合物输送剂和输送剂化合物
ATE311373T1 (de) 1999-02-11 2005-12-15 Emisphere Tech Inc Oxadiazolverbindungen und -zusammensetzungen zur abgabe von wirkstoffen
CA2364849A1 (en) 1999-02-26 2000-08-31 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
EP1175390B1 (en) 1999-04-05 2005-02-02 Emisphere Technologies, Inc. Disodium salts, monohydrates, and ethanol solvates
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
ATE427925T1 (de) 1999-11-05 2009-04-15 Emisphere Tech Inc Phenoxycarbonsaureverbindungen und zusammensetzungen zur verabreichung aktiver wirkstoffe
EP1237872B1 (en) 1999-12-16 2008-02-27 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
AU2001236457A1 (en) 2000-01-13 2001-07-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
PT1695983E (pt) * 2000-06-16 2009-05-05 Lilly Co Eli Análogos do peptídeo-1 do tipo glucagon
UA80248C2 (en) 2000-06-29 2007-09-10 Compounds and compositions for delivering active agents
NZ527157A (en) * 2001-03-01 2005-04-29 Emisphere Tech Inc Compositions for delivering bisphosphonates
WO2002100338A2 (en) 2001-06-08 2002-12-19 Emisphere Technologies, Inc. Compound and composition for delivering active agents
EP1453816B1 (en) 2001-11-13 2013-09-18 Emisphere Technologies, Inc. Phenoxy amine compounds and compositions for delivering active agents
MXPA04008068A (es) * 2002-02-20 2004-11-26 Lilly Co Eli Metodo para administrar moleculas de glp-1.
AU2004204727B8 (en) 2003-01-06 2006-11-09 Emisphere Technologies, Inc. Night-time oral insulin therapy
US20060286129A1 (en) * 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2195443C2 (ru) * 1996-07-31 2002-12-27 Байер Корпорейшн Замещенные биарильные соединения или замещенные пиридины и фармацевтические композиции на их основе
RU2247575C2 (ru) * 1999-01-14 2005-03-10 Амилин Фармасьютикалз, Инк. Способы подавления глюкагона
US6329336B1 (en) * 1999-05-17 2001-12-11 Conjuchem, Inc. Long lasting insulinotropic peptides

Also Published As

Publication number Publication date
JP5657230B2 (ja) 2015-01-21
US20090286735A1 (en) 2009-11-19
US20110178006A1 (en) 2011-07-21
US20140005106A1 (en) 2014-01-02
IL163278A (en) 2014-02-27
KR20110058863A (ko) 2011-06-01
EP1478233A2 (en) 2004-11-24
WO2003072195A3 (en) 2004-03-25
RU2004127916A (ru) 2005-04-10
US8492330B2 (en) 2013-07-23
IL230315A (en) 2016-11-30
CN1332711C (zh) 2007-08-22
US20150202296A1 (en) 2015-07-23
JP4417113B2 (ja) 2010-02-17
US20050148497A1 (en) 2005-07-07
EP2409569A3 (en) 2012-04-18
EP1478233B1 (en) 2016-11-09
JP2010006836A (ja) 2010-01-14
JP2005524658A (ja) 2005-08-18
CA2473340A1 (en) 2003-09-04
KR20040085205A (ko) 2004-10-07
EP2409569B1 (en) 2017-08-16
CN1635832A (zh) 2005-07-06
US7939494B2 (en) 2011-05-10
EP2409569A2 (en) 2012-01-25
ES2614603T3 (es) 2017-06-01
MXPA04008068A (es) 2004-11-26
ZA200406626B (en) 2005-11-30
AU2003208945A1 (en) 2003-09-09
BR0307727A (pt) 2005-01-25
PL209734B1 (pl) 2011-10-31
AU2003208945B2 (en) 2008-05-01
CA2473340C (en) 2014-12-09
PL371736A1 (en) 2005-06-27
EP1478233A4 (en) 2009-09-02
WO2003072195A2 (en) 2003-09-04
KR101165431B1 (ko) 2012-07-12
NZ534125A (en) 2006-11-30

Similar Documents

Publication Publication Date Title
RU2332229C2 (ru) Способ введения молекул glp-1
RU2376314C2 (ru) Стабилизированные соединения эксендина-4
JP4677095B2 (ja) エキセンジンおよびｇｌｐ−１の変力および利尿効果
US8785381B2 (en) Oral GLP-1 formulations
AU756836B2 (en) Novel exendin agonist compounds
BR112013029409B1 (pt) Produto de peptídeo compreendendo tensoativo ligado de forma covalente a peptídeo, composição farmacêutica que o compreende, bem como uso de produto de peptídeo no tratamento de condição associada à resistência à insulina, doença cardiovascular e diabetes
BR112015011478B1 (pt) Produtos de peptídeo, seus usos e composição farmacêutica
JP2005508895A (ja) Ｇｌｐ−１および基礎インスリンの予備混合物
CN106715466A (zh) 作为选择性胰高血糖素受体激动剂的毒蜥外泌肽‑4衍生物
HK1166449B (en) Method for administering glp-1 molecules
HK1166449A (en) Method for administering glp-1 molecules

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20070719

FZ9A Application not withdrawn (correction of the notice of withdrawal)

Effective date: 20070907